{"product_id":"anticancer-drug-resistance-advances-in-molecular-and-clinical-research-von-lori-j-goldstein-robert-f-ozols-hrsg","title":"Anticancer Drug Resistance","description":"\n                                Over the last 50 years, drug development and clinical trials  have resulted in successful complete responses in diseases such as  childhood leukemia, testicular cancer and Hodgkin's disease. We are  still, however, confronted with over 500,000 cancer-related deaths per  year. Clearly, the phenomenon of drug resistance is largely  responsible for these failures and continues to be an area of active  investigation. \n                \n                \u003cbr\u003e\n                                  Since the last volume in this series, we have learned that the  energy-dependent drug efflux protein, p-glycoprotein, encoded by the  \n                \n                \u003cem\u003eMDR\u003c\/em\u003e\n                                 1 gene, is a member of a family of structurally related  transport polypeptides, thus allowing us to explore the relationship  between structure and function. In addition to ongoing well designed  clinical trials aimed at reversing MDR mediated drug resistance, the  first gene therapy studies with the \n                \n                \u003cem\u003eMDR\u003c\/em\u003e\n                                 1 gene retrovirally  transduced into human bone marrow cells are about to be initiated.  \n                \n                \u003cbr\u003e\n                                  Although MDR is currently the most understood mechanism of drug  resistance, we are uncovering increasing knowledge of alternative  molecular and biochemical mechanisms of drug resistance to  antimetabolites, cisplatin and alkylating agents and developing new  strategies for circumventing such resistance. \n                \n                \u003cbr\u003e\n                                  It is clear that drug resistance is complex, and many mechanisms exist  by which cancer cells may overcome the cytotoxicity of our known  chemotherapeutic agents. As our understanding of each of these  mechanisms expands, well designed models will be necessary to test  laboratory hypotheses and determine their relationship to drug  resistance in humans. It is this integration of basic science and  clinical investigation that will both advance our scientific knowledge  and result in the improvement of cancer therapy. \n                \n                \u003cbr\u003e\n                            \n            \u003cdiv class=\"aw-variant-hidden-subtitle-div\" id=\"aw-variant-subtitle-9780792328360\"\u003e\u003ch3\u003eAdvances in Molecular and Clinical Research\u003c\/h3\u003e\u003c\/div\u003e\u003cdiv class=\"aw-variant-hidden-subtitle-div\" id=\"aw-variant-subtitle-9781461361299\"\u003e\u003ch3\u003eAdvances in Molecular and Clinical Research\u003c\/h3\u003e\u003c\/div\u003e","brand":"Libri","offers":[{"title":"Hardcover - 9780792328360","offer_id":50726373446,"sku":"9780792328360","price":213.99,"currency_code":"EUR","in_stock":true},{"title":"Softcover - 9781461361299","offer_id":39415534256221,"sku":"9781461361299","price":213.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0940\/0622\/files\/bdcc8d7a-70cb-473e-a5c3-701ffcf22e1b.jpg?v=1765862456","url":"https:\/\/shop.autorenwelt.de\/products\/anticancer-drug-resistance-advances-in-molecular-and-clinical-research-von-lori-j-goldstein-robert-f-ozols-hrsg","provider":"Autorenwelt Shop","version":"1.0","type":"link"}